Alligator Bioscience Awarded New Patent for its Protein Optimization
Technology FIND® in Japan
(Thomson Reuters ONE) - Lund, Sweden, December 2, 2009 - Alligator Bioscience AB, the proteinoptimization company, today announces that the Japan Patent Officehas granted the patent application JP 2004-506491 for its proteinoptimization platform, FIND® (Fragment Induced Diversity). With thispatent Alligator Bioscience will have coverage for it's methods inall major markets.The newly-granted patent describes methods of optimization of proteinproperties and functionalities by in vitro evolution usingrecombination of single stranded DNA.By their very nature, proteins have not primarily been developed toact as drugs and completely different requirements might be imposedfor this function. Our FIND® technology can overcome theselimitations and redesign virtually any characteristics of a proteinthat can be translated into significant clinical benefits, includinghigher efficacy and potency, improved safety profile and decreasedimmunogenicity. "The newly-granted patent in Japan confirms the strength of ourexpanding portfolio." said Gun-Britt Fransson, chief executiveofficer of Alligator Bioscience. "The patent covers the core of ourcompany, our proprietary FIND® technology. This platform enables usto build a competitive pipeline of novel and improved versions ofbiopharmaceuticals. We focus on candidates in inflammation and cancerand our disclosed programs targets the C5a receptor (C5aR),Interleukin 1 (IL-1) and Interleukin 23 (IL-23). We believe thispatent will be of crucial importance for our future development onthe Japanese market."About FIND®FIND® is a rapid in vitro evolution technology that mimics thenatural process of creating protein diversity through recombination.Our FIND® technology introduces mutations and recombines these intothe most favourable combinations. Our FIND® technology offers uniqueopportunities to discover novel protein drug candidates as well ascreating second generation biopharmaceuticals.About Alligator Bioscience ABAlligator Bioscience AB is a privately owned drug discovery anddevelopment company focused on optimization of biopharmaceuticalsusing it's proprietary protein optimization technology FIND®(Fragment INduced Diversity).Founded in 2001 in Lund, Sweden, Alligator Bioscience hassuccessfully collaborated with many companies in the pharmaceuticaland biotech industry, improving customers' proteins and helping themto build more competitive pipelines. Alligator Bioscience's ownpipeline of novel and improved drug candidates is focused oninflammation and cancer, including programs targeting the C5areceptor (C5aR), Interleukin 1 (IL-1) and Interleukin 23 (IL-23).Contacts:Alligator Bioscience ABDr Gun-Britt Fransson, CEOSchelevägen 19ASE-223 70 Lund, SwedenTel: +46 (0)46-2864280Fax: +46 (0)46-2864290http://hugin.info/134803/R/1358625/330861.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 02.12.2009 - 09:56 Uhr
Sprache: Deutsch
News-ID 9134
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 452 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Alligator Bioscience Awarded New Patent for its Protein Optimization
Technology FIND® in Japan"
steht unter der journalistisch-redaktionellen Verantwortung von
Alligator Bioscience AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
